Light Horse emerges with $62m and Novartis partnership worth up to $1bn
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
FierceBiotech22h
Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
BioSpace2d
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
FierceBiotech2d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
STAT2d
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
Investment Executive23h
Financial services consolidation ahead
On Wednesday, New York-headquartered Focus Financial Partners announced plans to make Cardinal Point, which it acquired in ...